J Gastroenterol Hepatol Endosc | Volume 2, Issue 5 | Case Report | Open Access
Rafaelle Galiotto Furlan1, Jonathan Soldera1,2, Rafael Sartori Balbinot1, Alana Zulian Terres1, Silvana Sartori Balbinot1,2 and Raul Angelo Balbinot1,2*
1Gastroenterology and Digestive Endoscopy Service, General Hospital of University of Caxias do Sul, Brazil
2Department of Gastroenterology, University of Caxias do Sul, Brazil
*Correspondance to: Raul Angelo Balbinot
Fulltext PDFUlcerative proctossigmoiditis is one of the presentations of ulcerative colitis, whose main etiological tripod is the modification of the intestinal bacterial microbiota, genetic predisposition and exposure to environmental antigenic factors. Individuals with inflammatory bowel disease are predisposed to severe and recurrent infections with Clostridium difficile, presenting high morbidity and mortality rates if treatment is not instituted early. The use of vancomycin as the first line in the therapeutic arsenal was effective in reducing the recurrence of C. difficile infection and complications of ulcerative colitis. In cases of relapse and not responsive to antibiotic therapy, fecal microbiota transplantation is used as a safe and effective therapy to restore the mucosal protection barrier through intestinal dacolonization by healthy bacterial flora. This case report confirms the positive therapeutic response to the use of fecal microbiota transplantation in a patient with ulcerative proctosigmoiditis for treatment of recurrent Clostridium infection.
Proctosigmoiditis; Exacerbated proctosigmoiditis; Clostridium difficile; Clostridium recidivant; Ulcerative colitis; Inflammatory bowel disease; Vancomycin; Fecal microbiota transplantation
Furlan RG, Soldera J, Balbinot RS, Terres AZ, Balbinot SS, Balbinot RA. Ulcerative Proctosigmoiditis Exacerbated by Recurrent Clostridium colitis: Case Report. J Gastroenterol Hepatol Endosc. 2017;2(5):1025.